VKH
MBRX icon

Virtu KCG Holdings’s Moleculin Biotech MBRX Stock Holding History

Virtu KCG Holdings’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$676K Buy
161
+57
+55% +$124K 0.02% 875
2017
Q1 		$274K Buy
+104
New +$364K 0.01% 2049
2016
Q4 		– Sell
-5
Closed -$66K – 3643
2016
Q3 		$66K Buy
+5
New +$72.1K ﹤0.01% 2735

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu KCG Holdings's MBRX Position: Q2 2017 in Review

Virtu KCG Holdings increased its Moleculin Biotech (MBRX) stake by 55% in Q2 2017, buying an estimated $124K and bringing the position to 161 shares worth $676K. The position accounts for 0.02% of the portfolio, ranked #875.

Virtu KCG Holdings first reported a position in MBRX in Q3 2016 and has held it in 3 quarters since. 13 funds tracked by Wall St. Rank hold MBRX as of Q2 2017.

  • Virtu KCG Holdings held 161 shares of Moleculin Biotech worth $676K as of Q2 2017.
  • Virtu KCG Holdings bought 57 Moleculin Biotech shares in Q2 2017, an estimated $124K.
  • Moleculin Biotech made up 0.02% of Virtu KCG Holdings's portfolio in Q2 2017, its #875 holding.
  • Virtu KCG Holdings first reported a position in Moleculin Biotech in Q3 2016 and has held it in 3 quarters since.
  • 13 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.